As part of our Pathway to Trials education series, we’re excited to share that Actio Biosciences has announced that their KCNT1 program is advancing into preclinical testing.
Join our upcoming webinar where foundation founder, Dr Justin West sits down with Actio co-founder, Dr David Goldstein who will share research findings and its significance for the KCNT1 community. It’s an exciting time to stay informed and explore what’s ahead.
Registration required: https://us02web.zoom.us/…/register/LXfrLtZlQOOHrHAT_csMTg
